National reccomendations for the management of patients with haemophilia
Abstract
The document presents recommendations for the comprehensive treatment of patients with haemophilia in Slovenia. It enables health workers at all three levels of health care to become well-acquainted with all the possible aspects of treatment based on the best practices of major centres worldwide, and on the studies and experience of health professionals at the National Haemophilia Centre, University Medical Center Ljubljana. The document contains definitions, treatment algorithms and lists of medications with their characteristics and appropriate dosages. It specifically defines indications for the exclusive competence of the tertiary level in Ljubljana due to the actual availability of teams and laboratory options. It also contains an extensive list of the literature on haemophilia.
Downloads
References
Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.
Benedik-Dolničar M. Zdravljenje bolnikov s hemoflijo. Obz Zdr Nege. 1998;32(3/4):97–105.
Aronstam A, Rainsford SG, Painter MJ. Patterns of bleeding in adolescents with severe haemophilia A. Br Med J. 1979;1(6161):469–70.
White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Defnitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientifc and standardization committee of the International Society on Trombosis and Haemostasis. Tromb Haemost. 2001;85(3):560.
Blanchette VS, Key NS, Ljung LR, MancoJohnson MJ, Berg HM van den, Srivastava A, et al. Defnitions in hemophilia: communication from the SSC of the ISTH. J Tromb Haemost. 2014;12(11):1935–9.
Colvin BT, Astermark J, Fischer K, Gringeri A, Lassila R, Schramm W, et al. European principles of haemophilia care. Haemophilia. 2008;14(2):361–74.
Giangrande P, Seitz R, Behr-Gross ME, Berger K, Hilger A, Klein H, et al. Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia. 2014;20(3):322–5.
Benedik Dolničar M. Bolnik s hemoflijo v Sloveniji: od leta 1967 do danes. Zdrav Vestn. 2015;48(5):383–91.
Anžej Doma S, Preložnik Zupan I, Andoljšek D, Benedik Dolničar M. Staranje bolnikov s hudo obliko hemoflije: zapleti in pridružene bolezni. Zdrav Vestn Supl. 2012;81:153–60.
CLSI. Collection, transport, and processing of Blood Soecimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays; Approved Guideline–Fifh Edition. CLSI document H21-A5. Vol.28 No. 5. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
Moort I van, Cnossen I, Maat M de. Measurement of factor VIII for the diagnosis of haemophilia A. In: Haemophilia. Clinical and Laboratory aspects. Special Issue 5. ECAT Foundation; 2015. p. 19–21.
Farrugia A. Globalisation and blood safety. Blood Rev. 2009;23(3):123–8.
Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors’ Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia. 2008;14(4):671–84.
Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood. 2012;119(18):4108–14.
MASAC Recommendation Regarding the Use of Recombinant Clotting Factor Products with Respect to Pathogen Transmission. National Hemophilia Foundation. 2014 [cited 2017 May 7]. Available from: https://www.hemophilia.org/Researchers-HealthcareProviders/Medical-and-Scientific-AdvisoryCouncil-MASAC/MASAC-Recommendations/MASAC-Recommendation-Regarding-the-Useof-Recombinant-Clotting-Factor-Products-withRespect-to-Pathogen-Transmission.
Collins P, Chalmers E, Chowdary P, Keeling D, Mathias M, O’Donnell J, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22(4):487–98.
Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood. 2012;120(4):720–7.
Matino D, Lillicrap D, Astermark J, Dolan G, Kessler C, Lambert T, et al. Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. Haemophilia. 2014;20(2):200–6.
Santagostino E, Auerswald G, Benson G, Dolan G, Jiménez-Yuste V, Lambert T, et al. Switching treatments in haemophilia: is there a risk of inhibitor development? Eur J Haematol. 2015;94(4):284–9.
Gouw SC, Bom JG van der, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368(3):231–9.
Lee M, Morfni M, Schulman S, Ingerslev J. The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors–International Society on Trombosis and Haemostasis, Inc. ISTH: The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors. 2001 [cited 2017 May 8]. Available from: https://www.ist h.org/ membe rs/group_conte nt_view.asp?group=100348&id=159244.
EMA/CHMP/BPWP/144533/2009 Committee for medicinal products for human use (CHMP) Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. [cited 2017 May 8]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109692.pdf.
Ljung RCR. Intracranial haemorrhage in haemophilia A and B. Br J Haematol. 2008;140(4):378–84.
Aronstam A, McLellan DS, Wassef M, Mbatha PS. Effect of height and weight on the in vivo recovery of transfused factor VIII C. J Clin Pathol. 1982;35(3):289–91.
Ingram GI. Calculating the dose of factor VIII in the management of haemophilia. Br J Haematol. 1981;48(2):351–4.
Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001;40(11):815–32.
Henrard S, Speybroeck N, Hermans C. Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. Haematologica. 2013;98(9):1481–6.
Ahnström J, Berntorp E, Lindvall K, Björkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia. 2004;10(6):689–97.
Blanchette V, Shapiro AD, Liesner R, Hernandez F, Retzios AD, Schroth P, et al. Characterization of the Pharmacokinetics of rFVIII in Young PreSchool Children with Hemophilia, Including an Analysis of the Influence of Age and Body Weight. Blood. 2004;104(11):3084–3084.
Gale RF, Hird MF, Colvin BT. Management of a premature infant with moderate haemophilia A using recombinant factor VIII. Haemophilia. 1998;4(6):850–3.
Kraf KE, Verlaak R, Heijst AFJ van, Nováková I, Brons PPT. Management of haemophilia in three premature infants. Haemophilia. 2008;14(2):378–80.
Tarantino MD, Collins PW, Hay CRM, Shapiro AD, Gruppo RA, Berntorp E, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004;10(5):428–37.
Morfni M. Pharmacokinetics of factor VIII and factor IX. Haemophilia. 2003;9 Suppl 1:94–99;discussion 100.
Gascoigne EW, Dash CH, Harman C, Wilmot D. A retrospective survey on the safety of Replenine, a high-purity factor IX concentrate. Pharmacoepidemiol Drug Saf. 2004;13(3):187–95.
White GC, Beebe A, Nielsen B. Recombinant factor IX. Tromb Haemost. 1997;78(1):261–5.
Shapiro AD, Di Paola J, Cohen A, Pasi KJ, Heisel MA, Blanchette VS, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood. 2005;105(2):518–25.
Collins PW, Fischer K, Morfni M, Blanchette VS, Björkman S, International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17(1):2–10.
Ewenstein BM, Joist JH, Shapiro AD, Hofstra TC, Leissinger CA, Seremetis SV, et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion. 2002;42(2):190–7.
Berntorp E, Björkman S. Te pharmacokinetics of clotting factor therapy. Haemophilia. 2003;9(4):353–9.
Berntorp E, Andersson NG. Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products. Semin Tromb Hemost. 2016;42(5):518–25.
Björkman S, Blanchette VS, Fischer K, Oh M, Spotts G, Schroth P, et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Tromb Haemost. 2010;8(4):730–6.
Valentino LA, Pipe SW, Collins PW, Blanchette VS, Berntorp E, Fischer K, et al. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia. 2016;22(4):514–20.
Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20(5):607–15.
Lee CA, Chi C, Pavord SR, Bolton-Maggs PHB, Pollard D, Hinchcliffe-Wood A, et al. The obstetric and gynecological management of women with inherited bleeding disorders–review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization. Haemophilia. 2006;12(4):301–36.
Björkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood. 2012;119(2):612–8.
Iorio A, Keepanasseril A, Foster G, NavarroRuan T, McEneny-King A, Edginton AN, et al. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPSHemo): Study Protocol. JMIR Res Protoc. 2016;5(4):e239.
Álvarez-Román MT, Fernandez-Bello I, CorteRodríguez H de la, Hernández-Moreno AL, Martín-Salces M, Butta-Coll N, et al. Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT(®) in patients with severe haemophilia A without inhibitors. Haemophilia. 2017;23(1):e50–4.
Reiniger A, Spotts G, Low-Baselli A. Optimizing prophylaxis: development of an advate PK calculator and dosing medical device based on a bayesian population PK model: Oral Presentations. Haemophilia. 2014;20:15.
Suzuki A, Tomono Y, Korth-Bradley JM. Population pharmacokinetic modelling of factor IX activity afer administration of recombi nant factor IX in patients with haemophilia B. Haemophilia. 2016;22(5):e359–366.
Jones P. Looking after the veins. Montreal: World Federation of Hemophilia. 2003;23(2):215–221.
Hathaway WE, Christian MJ, Clarke SL, Hasiba U. Comparison of continuous and intermittent Factor VIII concentrate therapy in hemophilia A. Am J Hematol. 1984;17(1):85–8.
Bona RD, Weinstein RA, Weisman SJ, Bartolomeo A, Rickles FR. Te use of continuous infusion of factor concentrates in the treatment of hemophilia. Am J Hematol. 1989;32(1):8–13.
Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol. 1992;82(4):729–34.
Hay CR, Doughty HI, Savidge GF. Continuous infusion of factor VIII for surgery and major bleeding. Blood Coagul Fibrinolysis. 1996;7 Suppl 1:S15–19.
Batorova A, Holme P, Gringeri A, Richards M, Hermans C, Altisent C, et al. Continuous infusion in haemophilia: current practice in Europe. Haemophilia. 2012;18(5):753–9.
Prelog T, Dolničar MB, Kitanovski L. Low-dose continuous infusion of factor VIII in patients with haemophilia A. Blood Transfus. 2016;14(5):474–80.
Suzuki N, Hirakawa A, Kishimoto M, Kanematsu T, Ogawa M, Kiyoi H, et al. Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study. Haemophilia. 2016.
Auerswald G, Bade A, Haubold K, Overberg D, Masurat S, Moorthi C. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study. Haemophilia. 2013;19(3):438–44.
Mauser-Bunschoten EP, Den Uijl IEM, Schutgens REG, Roosendaal G, Fischer K. Risk of inhibitor development in mild haemophilia A increases with age. Haemophilia. 2012;18(2):263–7.
Benedik Dolničar M. Zdravljenje bolnikov s hemoflijo A z nepretrgano infuzijo koncentrata faktorja VIII. Zdrav Vestn. 1995;64(10):591–3.
Armstrong E, Astermark J, Baghaei F, Berntorp E, Brodin E, Clausen N, et al. Nordic Hemophilia guidelines. Nordic Hemophilia Council; 2015.
Suzuki N, Takedani H, Hirakawa A, Ushijima Y, Matsushita T. Te features of clearance in recombinant factor IX (BeneFIX(®) ). Haemophilia. 2015;21(5):702–7.
Revel-Vilk S, Blanchette VS, Schmugge M, Clark DS, Lillicrap D, Rand ML. In vitro and in vivo stability of diluted recombinant factor VIII for continuous infusion use in haemophilia A. Haemophilia. 2010;16(1):72–9.
Parti R, Ardosa J, Yang L, Mankarious S. In vitro stability of recombinant human factor VIII (Recombinate). Haemophilia. 2000;6(5):513–22.
Belgaumi AF, Patrick CC, Deitcher SR. Stability and sterility of a recombinant factor VIII concentrate prepared for continuous infusion administration. Am J Hematol. 1999;62(1):13–8.
Chowdary P, Dasani H, Jones JA, Loran CM, Eldridge A, Hughes S, et al. Recombinant factor IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical experience. Haemophilia. 2001;7(2):140–5.
Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-defcient women. Blood. 2005;105(8):3382.
Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 1997;90(7):2515–21.
Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol. 1992;82(1):87–93.
Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand’s disease. Br J Haematol. 1981;47(2):283–93.
Castaman G, Tosetto A, Rodeghiero F. Pregnancy and delivery in women with von Willebrand’s disease and different von Willebrand factor mutations. Haematologica. 2010;95(6):963–9.
Trigg DE, Stergiotou I, Peitsidis P, Kadir RA. A systematic review: The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia. 2012;18(1):25–33.
Anderson J a. M, Brewer A, Creagh D, Hook S, Mainwaring J, McKernan A, et al. Guidance on the dental management of patients with haemophilia and congenital bleeding disorders. Br Dent J. 2013;215(10):497–504.
Khair K, Baker K, Mathias M, Burgess C, Liesner R. Intranasal desmopressin (Octim): a safe and effcacious treatment option for children with bleeding disorders. Haemophilia. 2007;13(5):548–51.
Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med.
;114(7):563–8.
Jiménez-Yuste V, Prim MP, De Diego JI, Villar A, Quintana M, Rabanal I, et al. Otolaryngologic surgery in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg. 2002;128(12):1365–8.
Witmer CM, Manno CS, Butler RB, Rafni LJ. The clinical management of hemophilia and head trauma: a survey of current clinical practice among pediatric hematology/oncology physicians. Pediatr Blood Cancer. 2009;53(3):406–10.
Mason JA, Robertson JD, McCosker J, Williams BA, Brown SA. Assessment and validation of a defined fluid restriction protocol in the use of subcutaneous desmopressin for children with inherited bleeding disorders. Haemophilia. 2016;22(5):700–5.
Mannucci PM. Problems in hemophilia therapy. Ric Clin Lab. 1981;11(4):301–11.
Franchini M, Zaffanello M, Lippi G. Te use of desmopressin in mild hemophilia A. Blood Coagul Fibrinolysis. 2010;21(7):615–9.
Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders. Montreal: World Federation of Hemophilia. [cited 2017 May 9]. Available from: http://www1.wf.org/publication/fles/pdf-1131.pdf.
DDAVP–FDA prescribing information, side effects and uses. [cited 2017 May 8]. Available from: https://www.drugs.com/pro/ddavp.html.
Gomez García EB, Ruitenberg A, Madretsma GS, Hintzen RQ. Hyponatraemic coma induced by desmopressin and ibuprofen in a woman with von Willebrand’s disease. Haemophilia. 2003;9(2):232–4.
Castaman G, Mancuso ME, Giacomelli SH, Tosetto A, Santagostino E, Mannucci PM, et al. Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A. J Tromb Haemost. 2009;7(11):1824–31.
Mannucci PM. Hemostatic drugs. N Engl J Med. 1998;339(4):245–53.
Hvas A-M, Sørensen HT, Norengaard L, Christiansen K, Ingerslev J, Sørensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fbrinolysis in severe hemophilia A. J Tromb Haemost. 2007;5(12):2408–14.
Tranexamic Acid Injection–FDA prescribing information, side effects and uses. Drugs.com. [cited 2017 May 9]. Available from: https://www.drugs.com/pro/tranexamic-acid-injection.html.
Ambados F. Preparing tranexamic acid 4.8 % mouthwash. NPS MedicineWise. 2003 [cited 2016 Dec 26]. Available from: /australian-prescriber/articles/preparing-tranexamic-acid-4–8-mouthwash.
Queale R, Buckley M. Afer Tooth Extraction Greensburg PA. 2017 [cited 2017 May 19]. Available from: http://www.westmorelandoms.com/surgical-instructions/tooth-extractions-greensburg.aspx.
Fischer K, Collins PW, Ozelo MC, Srivastava A, Young G, Blanchette VS. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. J Tromb Haemost. 2016;14(5):1105–9.
Chan MW, Leckie A, Xavier F, Uleryk E, Tadros S, Blanchette V, et al. A systematic review of MR imaging as a tool for evaluating haemophilic arthropathy in children. Haemophilia. 2013;19(6):e324–334.
Seuser A, Berdel P, Oldenburg J. Rehabilitation of synovitis in patients with haemophilia. Haemophilia. 2007;13 Suppl 3:26–31.
Mancuso ME, Graca L, Auerswald G, Santagostino E. Haemophilia care in children-benefts of early prophylaxis for inhibitor prevention. Haemophilia. 2009;15 Suppl 1:8–14.
Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia. 2010;16(2):256–62.
Auerswald G, Bidlingmaier C, Kurnik K. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients—long-term follow-up and continuing experience. Haemophilia. 2012;18(1):e18–20.
Gouw SC, Berg HM van den, Cessie S le, Bom JG van der. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Tromb Haemost. 2007;5(7):1383–90.
Van Den Berg H. Vaccination are not Increasing the Risk for Inhibitor Development–oral presentation. Haemophilia. 2017;23:11–27.
Donadel-Claeyssens S, European Paediatric Network for Haemophilia Management. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia. 2006;12(2):124–7.
Hermans C, De Moerloose P, Fischer K, Holstein K, Klamroth R, Lambert T, et al. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. Haemophilia. 2011;17(3):383–92.
Rodriguez-Merchan EC. Aspects of current management: orthopaedic surgery in haemophilia. Haemophilia. 2012;18(1):8–16.
Rodriguez-Merchan EC, Jimenez-Yuste V. The role of selective angiographic embolization of the musculo-skeletal system in haemophilia. Haemophilia. 2009;15(4):864–8.
Rukavina A, Kerkhoffs GMMJ, Schneider P, Kuster MS. Recurrent hemarthrosis after total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2010;18(7):898–900.
Mounasamy V, Dawson C, Cui Q, Mihalko WM, Saleh KJ, Brown T. Popliteal artery pseudoaneurysm following total knee arthroplasty: a case report. Eur J Orthop Surg Traumatol. 2007;17(3):313–5.
Ashrani AA, Osip J, Christie B, Key NS. Iliopsoas haemorrhage in patients with bleeding disorders—experience from one centre. Haemophilia. 2003;9(6):721–6.
Balkan C, Kavakli K, Karapinar D. Iliopsoas haemorrhage in patients with haemophilia: results from one centre. Haemophilia. 2005;11(5):463–7.
Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia. 1995;1 Suppl 1:8–13.
Patiroglu T, Ozdemir MA, Unal E, Altuner Torun Y, Coskun A, Menku A, et al. Intracranial hemorrhage in children with congenital factor defciencies. Childs Nerv Syst. 2011;27(11):1963–6.
Zanon E, Iorio A, Rocino A, Artoni A, Santoro R, Tagliaferri A, et al. Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. Haemophilia. 2012;18(1):39–45.
Singleton T, Kruse-Jarres R, Leissinger C. Emergency department care for patients with hemophilia and von Willebrand disease. J Emerg Med. 2010;39(2):158–65.
Bush MT, Roy N. Hemophilia emergencies. J Emerg Nurs. 1995;21(6):531–538;quiz 538–540.
Kouides PA, Fogarty PF. How do we treat: upper gastrointestinal bleeding in adults with haemophilia. Haemophilia. 2010;16(2):360–2.
Mittal R, Spero JA, Lewis JH, Taylor F, Ragni MV, Bontempo FA, et al. Patterns of gastrointestinal hemorrhage in hemophilia. Gastroenterology. 1985;88(2):515–22.
Rodeghiero F. Te incidence of renal disease in patients with hemophilia. The international monitor. Reviews of Current Literature in Hemophilia. 2004;2004(2):16–7.
Benedik-Dolnicar M, Benedik M. Haematuria in patients with haemophilia and its influence on renal function and proteinuria. Haemophilia. 2007;13(5):489–92.
Post T, Rose B. Urinalysis in the diagnosis of kidney disease–UpToDate. 2016 [cited 2017 May 10]. Available from: https://www.uptodate.com/contents/urinalysis-in-the-diagnosis-of-kidney-disease.
Quon DV, Konkle BA. How we treat: haematuria in adults with haemophilia. Haemophilia. 2010;16(4):683–5.
Ghosh K, Jijina F, Mohanty D. Haematuria and urolithiasis in patients with haemophilia. Eur J Haematol. 2003;70(6):410–2.
Escobar MA. Products used to Treat Hemophilia: Dosing. In: Lee CA, Berntorp EE, Hoots WK, Aledort LM, editors. Textbook of Hemophilia. Blackwell Publishing Ltd; 2005 [cited 2016 Dec 26]; p. 153–7. Available from: http://onlinelibrary.wiley.com/doi/10.1002/9780470987124.ch27/summary.
Sells H, Cox R. Undiagnosed macroscopic haematuria revisited: a follow-up of 146 patients. BJU Int. 2001;88(1):6–8.
Brewer AK, Roebuck EM, Donachie M, Hazard A, Gordon K, Fung D, et al. The dental management of adult patients with haemophilia and other congenital bleeding disorders. Haemophilia. 2003;9(6):673–7.
Scottish Dental Clinical Effectiveness Programme. Prevention and management of dental caries in children: dental clinical guidance. Dundee: Scottish Dental Clinical Effectiveness Programme. 2010 [cited 2017 May 10]. Available from: http://www.sdcep.org.uk/wp-content/uploads/2013/03/SDCEP_PM_Dental_Caries_Full_Guidance1.pdf.
Scottish Dental Clinical Effectiveness Programme. Oral health assessment and review: guidance in brief. Dundee: Scottish Dental Clinical Effectiveness Programme. 2011 [cited 2017 May 10]. Available from: http://www.sdcep.org.uk/published-guidance/oral-health-assessment/.
Hewson ID, Daly J, Hallett KB, Liberali SA, Scott CLM, Spaile G, et al. Consensus statement by hospital based dentists providing dental treatment for patients with inherited bleeding disorders. Aust Dent J. 2011;56(2):221–6.
Brewer A. Guidelines for dental treatment of patients with inherited bleeding disorders-On behalf of World Federation of Hemophilia Dental Committee. Treat Hemoph. 2006 [cited 2017 May 10]; 2006 (No 40). Available from: http://www1.wf.org/publication/fles/pdf-1190.pdf.
Freedman M, Dougall A, White B. An audit of a protocol for the management of patients with hereditary bleeding disorders undergoing dental treatment. J Disabili Oral Health. 2009;2009(10):151–5.
Smith G, Dougall A. To audit the success rate of using 4 % articaine as buccal infltration in order to anaesthetise mandibular molars for restorative dental treatment in patients with a hereditary coagulation disorder. Haemophilia. 2010;(16):51.
Robertson D, Nusstein J, Reader A, Beck M, McCartney M. The anesthetic efficacy of articaine in buccal infiltration of mandibular posterior teeth. J Am Dent Assoc. 2007;138(8):1104–12.
Heiland M, Weber M, Schmelzle R. Lifethreatening bleeding afer dental extraction in a hemophilia A patient with inhibitors to factor VIII: a case report. J Oral Maxillofac Surg. 2003;61(11):1350–3.
Dougall A, Fiske J. Access to special care dentistry, part 5. Safety. Br Dent J. 2008;205(4):177–90.
Zanon E, Martinelli F, Bacci C, Zerbinati P, Girolami A. Proposal of a standard approach to dental extraction in haemophilia patients. A case-control study with good results. Haemophilia. 2000;6(5):533–6.
Hermans C, Altisent C, Batorova A, Chambost H, De Moerloose P, Karafoulidou A, et al. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia. 2009;15(3):639–58.
Stajcić Z. The combined local/systemic use of antifbrinolytics in hemophiliacs undergoing dental extractions. Int J Oral Surg. 1985;14(4):339–45.
Sindet-Pedersen S, Stenbjerg S. Effect of local antifbrinolytic treatment with tranexamic acid in hemophiliacs undergoing oral surgery. J Oral Maxillofac Surg. 1986;44(9):703–7.
Sindet-Pedersen S. Distribution of tranexamic acid to plasma and saliva after oral administration and mouth rinsing: a pharmacokinetic study. J Clin Pharmacol. 1987;27(12):1005–8.
Lee APH, Boyle CA, Savidge GF, Fiske J. Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. Br Dent J. 2005;198(1):33–38.
Ljung RCR, Knobe K. How to manage invasive procedures in children with haemophilia. Br J Haematol. 2012;157(5):519–28.
Ak G, Cakir Q, Kazancioglu H, Zulfkar B. The use of a new haemostatic agent: Ankaferd Blood Stopper in haemophiliacs. Haemophilia. 2010;16:1–158.
Australian Haemophilia Centre Directors’ Organisation. Guideline for the management of patients with haemophilia undergoing surgical procedures [cited 2016 Dec 27]. Available from: http://www.ahcdo.org.au/documents/item/13.
Douketis JD. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians. Tromb Res. 2002;108(1):3–13.
Ljung R. Central venous catheters in children with haemophilia. Blood Rev. 2004;18(2):93–100.
Santagostino E, Mancuso ME. Barriers to primary prophylaxis in haemophilic children: the issue of the venous access. Blood Transfus. 2008;6 Suppl 2:s12–16.
Langley AR, Stain AM, Chan A, McLimont M, Chait S, Wu J, et al. Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS). Haemophilia. 2015;21(4):469–76.
Guillon P, Makhlouf M, Baillie S, Roucoulet C, Dolimier E, Masquelier A-M. Prospective evaluation of venous access difficulty and a near-infrared vein visualizer at four French haemophilia treatment centres. Haemophilia. 2015;21(1):21–6.
Santagostino E, Gringeri A, Muça-Perja M, Mannucci PM. A prospective clinical trial of implantable central venous access in children with haemophilia. Br J Haematol. 1998;102(5):1224–8.
Kempton CL, White GC. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood. 2009;113(1):11–7.
Rodriguez-Merchan EC. Aspects of current management: orthopaedic surgery in haemophilia. Haemophilia. 2012;18(1):8–16.
Seuser A, Boehm P, Kurme A, Schumpe G, Kurnik K. Orthopaedic issues in sports for persons with haemophilia. Haemophilia. 2007;13 Suppl 2:47–52.
Blamey G, Forsyth A, Zourikian N, Short L, Jankovic N, De Kleijn P, et al. Comprehensive elements of a physiotherapy exercise programme in haemophilia—a global perspective. Haemophilia. 2010;16 Suppl 5:136–45.
Gomis M, Querol F, Gallach JE, González LM, Aznar JA. Exercise and sport in the treatment of haemophilic patients: a systematic review. Haemophilia. 2009;15(1):43–54.
Rattray B, Nugent DJ, Young G. Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Haemophilia. 2006;12(5):514–7.
Tsoukas C, Eyster ME, Shingo S, Mukhopadhyay S, Giallella KM, Curtis SP, et al. Evaluation of the efcacy and safety of etoricoxib in the treatment of hemophilic arthropathy. Blood. 2006;107(5):1785–90.
Llinás A. The role of synovectomy in the management of a target joint. Haemophilia. 2008;14 Suppl 3:177–80.
Yoon KH, Bae DK, Kim HS, Song SJ. Arthroscopic synovectomy in haemophilic arthropathy of the knee. Int Orthop. 2005;29(5):296–300.
Tomas S, Gabriel MB, Assi PE, Barboza M, Perri MLP, Land MGP, et al. Radioactive synovectomy with Yttrium90 citrate in haemophilic synovitis: Brazilian experience. Haemophilia. 2011;17(1):e211–216.
Kasteren ME van, Nováková IR, Boerbooms AM, Lemmens JA. Long term follow up of radiosynovectomy with yttrium-90 silicate in haemophilic haemarthrosis. Ann Rheum Dis. 1993;52(7):548–50.
Grmek M, Milcinski M, Fettich J, BenedikDolnicar M, Brecelj J. Radiosynoviorthesis for treatment of hemophilic hemarthrosis—Slovenian experience. Cancer Biother Radiopharm. 2005;20(3):338–43.
Grmek M, Milcinski M, Fettich J, Brecelj J. Radiation exposure of hemophiliacs after radiosynoviorthesis with 186Re colloid. Cancer Biother Radiopharm. 2007;22(3):417–22.
Brecelj J, Bole V, Benedik-Dolnicar M, Grmek M. The co effect of prophylaxis and radiosynovectomy on bleeding episodes in haemophilic synovitis. Haemophilia. 2008;14(3):513–7.
Doria AS, Lundin B, Miller S, Kilcoyne R, Dunn A, Tomas S, et al. Reliability and construct validity of the compatible MRI scoring system for evaluation of elbows in haemophilic children. Haemophilia. 2008;14(2):303–14.
Keshava S, Gibikote S, Mohanta A, Doria AS. Refnement of a sonographic protocol for assessment of haemophilic arthropathy. Haemophilia. 2009;15(5):1168–71.
Zukotynski K, Jarrin J, Babyn PS, Carcao M, Pazmino-Canizares J, Stain AM, et al. Sonography for assessment of haemophilic arthropathy in children: a systematic protocol. Haemophilia. 2007;13(3):293–304.
Wiedel JD. Arthroscopic synovectomy: state of the art. Haemophilia. 2002;8(3):372–4.
Goddard NJ, Mann HA, Lee CA. Total knee replacement in patients with end-stage haemophilic arthropathy: 25-year results. J Bone Joint Surg Br. 2010;92(8):1085–9.
Silva M, Luck JV. Radial head excision and synovectomy in patients with hemophilia. Surgical technique. J Bone Joint Surg Am. 2008;90 Suppl 2 Pt 2:254–61.
Barg A, Elsner A, Hefi D, Hintermann B. Haemophilic arthropathy of the ankle treated by total ankle replacement: a case series. Haemophilia. 2010;16(4):647–55.
Tsailas PG, Wiedel JD. Arthrodesis of the ankle and subtalar joints in patients with haemophilic arthropathy. Haemophilia. 2010;16(5):822–31.
D’Young AI. Conservative physiotherapeutic management of chronic haematomata and haemophilic pseudotumours: case study and comparison to historical management. Haemophilia. 2009;15(1):253–60.
Rodriguez Merchan EC. The haemophilic pseudotumour. Int Orthop. 1995;19(4):255–60.
Alcalay M, Deplas A. Rheumatological management of patients with hemophilia. Part II: Muscle hematomas and pseudotumors. Joint Bone Spine. 2002;69(6):556–9.
Espandar R, Heidari P, Rodriguez-Merchan EC. Management of haemophilic pseudotumours with special emphasis on radiotherapy and arterial embolization. Haemophilia. 2009;15(2):448–57.
Rodriguez-Merchan EC. Bone fractures in the haemophilic patient. Haemophilia. 2002;8(2):104–11.
Lee VN, Srivastava A, Nithyananth M, Kumar P, Cherian VM, Viswabandya A, et al. Fracture neck of femur in haemophilia A–experience from a cohort of 11 patients from a tertiary centre in India. Haemophilia. 2007;13(4):391–4.
Mortazavi SMJ, Heidari P. Retrograde intramedullary nailing of supracondylar femoral fractures in haemophilic patients. Haemophilia. 2008;14(3):661–4.
De Kleijn P, Blamey G, Zourikian N, Dalzell R, Lobet S. Physiotherapy following elective ortho paedic procedures. Haemophilia. 2006;12 Suppl 3:108–12.
Meijer P, Verbruggen B. Te between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. Semin Tromb Hemost. 2009;35(8):786–93.
Verbruggen B, Heerde WL van, Laros-van Gorkom BAP. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen. Semin Tromb Hemost. 2009;35(8):752–9.
Sharathkumar A, Lillicrap D, Blanchette VS, Kern M, Leggo J, Stain AM, et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Tromb Haemost. 2003;1(6):1228–36.
Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol. 2013;160(2):153–70.
Kempton CL, Soucie JM, Miller CH, Hooper C, Escobar MA, Cohen AJ, et al. In non-severe hemophilia A the risk of inhibitor afer intensive factor treatment is greater in older patients: a case-control study. J Tromb Haemost. 2010;8(10):2224–31.
Verbruggen B, Novakova I, Wessels H, Boezeman J, Berg M van den, Mauser-Bunschoten E. The Nijmegen modifcation of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Tromb Haemost. 1995;73(2):247–51.
Darby SC, Keeling DM, Spooner RJD, Wan Kan S, Giangrande PLF, Collins PW, et al. Te incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. J Tromb Haemost. 2004;2(7):1047–54.
Hay CRM, Palmer B, Chalmers E, Liesner R, Maclean R, Rangarajan S, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood. 2011;117(23):6367–70.
Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia. 2006;12 Suppl 6:15–22.
Moerloose P de, Fischer K, Lambert T, Windyga J, Batorova A, Lavigne-Lissalde G, et al. Recommendations for assessment, monitoring and follow-up of patients with haemophilia. Haemophilia. 2012;18(3):319–25.
Berntorp E, Collins P, D’Oiron R, Ewing N, Gringeri A, Négrier C, et al. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus defnition. Haemophilia. 2011;17(1):e202–210.
McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. Te natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood. 1988;71(2):344–8.
Peyvandi F, Mannucci PM, Garagiola I, ElBeshlawy A, Elalfy M, Ramanan V, et al. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016;374(21):2054–64.
Hay CRM. Trombosis and recombinant factor VIIa. J Tromb Haemost. 2004;2(10):1698–9.
Teitel J, Berntorp E, Collins P, D’Oiron R, Ewenstein B, Gomperts E, et al. A systematic approach to controlling problem bleeds
in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia. 2007;13(3):256–63.
Shibata M, Nakagawa T, Akioka S, Giddings JC, Kanehiro H, Matsumoto T, et al. Hemostatic treatment using factor VIII concentrates for neutralizing high-responding inhibitors prior to CVAD insertion for immune-tolerance induction therapy. Clin Appl Tromb. 2012;18(1):66–71.
Kulkarni R. Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: practical aspects. Haemophilia. 2013;19(1):2–10.
Kasper CK. Treatment of factor VIII inhibitors. Prog Hemost Tromb. 1989;9:57–86.
Van Leeuwen EF, Mauser-Bunschoten EP, Van Dijken PJ, Kok AJ, Sjamsoedin-Visser EJ, Sixma JJ. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low
dose. Br J Haematol. 1986;64(2):291–7.
Ewing N, Escuriola-Ettingshausen C, Kreuz W. Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors. Haemophilia. 2015;21(3):358–64.
Negrier C, Voisin S, Baghaei F, Numerof R, Novack A, Doralt JE, et al. Global PostAuthorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate). Blood Coagul Fibrinolysis. 2016;27(5):551–6.
Ettingshausen CE, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series. Haemophilia. 2010;16(1):90–100.
Rangarajan S, Austin S, Goddard NJ, Négrier C, Rodriguez-Merchan EC, Stephensen D, et al. Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery. Haemophilia. 2013;19(2):294–303.
Astermark J, Donfeld SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546–51.
Berntorp E, Shapiro A, Astermark J, Blanchette VS, Collins PW, Dimichele D, et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia. 2006;12 Suppl 6:1–7.
Ingerslev J, Sørensen B. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol. 2011;155(2):256–62.
Luu H, Ewenstein B. FEIBA safety profle in multiple modes of clinical and home-therapy application. Haemophilia. 2004;10 Suppl 2:10–6.
Windyga J, Stefanska-Windyga E, Odnoczko E, Baran B, Czubak G. Activated prothrombin complex concentrate in combination with tranexamic acid: a single centre experience for the treatment of mucosal bleeding and dental extraction in haemophilia patients with inhibitors. Haemophilia. 2016;22(5):e465–468.
Giangrande PLF, Wilde JT, Madan B, Ludlam CA, Tuddenham EGD, Goddard NJ, et al. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia. 2009;15(2):501–8.
Rodriguez-Merchan EC, Rocino A, Ewenstein B, Bartha L, Batorova A, Goudemand J, et al. Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia. 2004;10 Suppl 2:50–2.
Belvini D, Salviato R, Radossi P, Pierobon F, Mori P, Castaldo G, et al. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica. 2005;90(5):635–42.
Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey. Haemophilia. 1996;2(1):28–31.
Darby SC, Keeling DM, Spooner RJD, Wan Kan S, Giangrande PLF, Collins PW, et al. Te incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. J Tromb Haemost. 2004;2(7):1047–54.
Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX defciency a report of the ISTH-SSC international FIX inhibitor registry (1997–2006). Haemophilia. 2009;15(5):1027–31.
Recht M, Pollmann H, Tagliaferri A, Musso R, Janco R, Neuman WR. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia. 2011;17(3):494–9.
Rocino A, Cortesi PA, Scalone L, Mantovani LG, Crea R, Gringeri A, et al. Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (Te ITER Study). Haemophilia. 2016;22(1):96–102.
Kreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, et al. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. Haemophilia. 2016;22(1):87–95.
Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003;9(4):436–63.
DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007;13 Suppl 1:1–22.
Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang. 1999;77 Suppl 1:33–7.
Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Tromb Haemost. 1994;72(1):155–8.
Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, Berg HM van den. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood. 1995;86(3):983–8.
Nakar C, Manco-Johnson MJ, Lail A, Donfeld S, Maahs J, Chong Y, et al. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres. Haemophilia. 2015;21(3):365–73.
Hay CRM, DiMichele DM, International Immune Tolerance Study. Te principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119(6):1335–44.
Lenk H. Te German National Immune Tolerance Registry, 1997 update. Study Group of German Haemophilia Centres. Vox Sang. 1999;77 Suppl 1:28–30.
Di Minno G, Coppola A. A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors? Blood Transfus. 2011;9 Suppl 2:s14–20.
Ter Avest PC, Fischer K, Gouw SC, Van Dijk K, Mauser-Bunschoten EP. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. Haemophilia. 2010;16(102):71–9.
Brackmann HH, Lenk H, Scharrer I, Auerswald G, Kreuz W. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia. 1999;5(3):203–6.
Mateo J, Badell I, Forner R, Borrell M, Tizzano E, Fontcuberta J. Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: an example of a significant decrease of treatment costs. Tromb
Haemost. 2006;95(2):386–7.
Franchini M, Mannucci PM. Inhibitor eradication with rituximab in haemophilia: where do we stand? Br J Haematol. 2014;165(5):600–8.
Robertson JD, Higgins P, Price J, Dunkley S, Barrese G, Curtin J. Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE), with or without immunosuppression, in Australian pediatric severe haemophilia A patients with high titre inhibitors: a multicentre, retrospective study. Tromb Res. 2014;134(5):1046–51.
Callaghan MU, Fogarty PF. What is the evidence for the use of immunomodulatory agents to eradicate inhibitory antibodies in patients with severe hemophilia a who have previously failed to respond to immune tolerance induction? Hematology. 2011;2011(1):405–6.
DeFrates SR, McDonagh KT, Adams VR. The reversal of inhibitors in congenital hemophilia. Pharmacotherapy. 2013;33(2):157–64.
European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153–94.
Sočan M, Tomažič J, Šubelj M, Fafangel M, Trop, Skaza A. Ukrepi ob poškodbi z ostrim predmetom, ki je onesnažen s krvjo ali drugim telesnim izločkom zunaj zdravstva. Zdrav Vestn. 2013;(82):535–44.
Hamborsky J, Kroger A, Wolfe S, editor. Centers for Disease Control and Prevention. Epidemiology and Prevention of VaccinePreventable Diseases. 13th ed. Washington D.C.: Public Health Foundation; 2015.
Matičič M, Poljak M. Slovenske nacionalne usmeritve za preprečevanje reaktivacije hepatitisa B pri bolnikih, ki potrebujejo imunosupresivno zdravljenje. Zdrav Vestn. 2010;(79):599–608.
Lampertico P, Berg T, Buti M, Janssen HLA, Papatheodoridis G, Zoulim F, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017. doi: 10.1016/j.jhep.2017.03.021.
Mannucci PM, Gringeri A, Savidge G, Gatenby P, Laurian Y, Pabinger-Fasching I, et al. Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group. Br J Haematol. 1994;86(1):174–9.
Ragni MV, Amato DA, LoFaro ML, DeGruttola V, Van Der Horst C, Eyster ME, et al. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodefciency virus-1 infection. AIDS Clinical Trial Groups. Blood. 1995;85(9):2337–46.
Humphreys EH, Chang LW, Harris J. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. Cochrane Database Syst Rev. 2010;16(6):CD006517.
Spaulding A, Rutherford GW, Siegfried N. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev. 2010;(8):CD008651.
Spaulding A, Rutherford GW, Siegfried N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviralnaïve individuals. Cochrane Database Syst Rev. 2010;(10):CD008740.
Reust CE. Common adverse effects of antiretroviral therapy for HIV disease. Am Fam Physician. 2011;83(12):1443–51.
Kempton CL, Antoniucci DM, RodriguezMerchan EC. Bone health in persons with haemophilia. Haemophilia. 2015;21(5):568–77.
Compston J. HIV infection and osteoporosis. Bonekey Rep. 2015;4:636.
Castaman G, Eckhardt C, Velzen A van, Linari S, Fijnvandraat K. Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A. Semin Tromb Hemost. 2016;42(5):507–12.
Aledort LM. Can we prevent inhibitors in mild and moderate factor VIII-defcient patients? J Tromb Haemost. 2006;4(4):914.
Eckhardt CL, Velzen AS van, Peters M, Astermark J, Brons PP, Castaman G, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013;122(11):1954–62.
Mauser-Bunschoten EP, Den Uijl IEM, Schutgens REG, Roosendaal G, Fischer K. Risk of inhibitor development in mild haemophilia A increases with age. Haemophilia. 2012;18(2):263–7.
Fijnvandraat K, Turenhout EA, Brink EN van den, Cate JW ten, Mourik JA van, Peters M, et al. The missense mutation Arg593 —> Cys is related to antibody formation in a patient with mild hemophilia A. Blood. 1997;89(12):4371–7.
Tompson AR, Murphy ME, Liu M, Saenko EL, Healey JF, Lollar P, et al. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation. Blood. 1997;90(5):1902–10.
Jacquemin M, De Maeyer M, D’Oiron R, Lavend’Homme R, Peerlinck K, Saint-Remy J-M. Molecular mechanisms of mild and moderate hemophilia A. J Tromb Haemost. 2003;1(3):456–63.
Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia. 1998;4(4):558–63.
Dunkley S, Kershaw G, Young G, Warburton P, Lindeman R, Matthews S, et al. Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol. Haemophilia. 2006;12(6):663–7.
Franchini M, Mengoli C, Lippi G, Targher G, Montagnana M, Salvagno GL, et al. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients’ analysis. Haemophilia. 2008;14(5):903–12.
Benedik Dolničar MB, Rajić V, Kitanovski L, Debeljak M. Rituximab for the treatment of high titre inhibitors in mild haemophilia A. Blood Transfus. 2014;12 Suppl 1:s345–347.
Lim MY, Nielsen B, Lee K, Kasthuri RS, Key NS, Ma AD. Rituximab as frst-line treatment for the management of adult patients with non-severe hemophilia A and inhibitors. J Tromb Haemost. 2014;12(6):897–901.
Carriers and Women with Hemophilia. Montreal: World Federation of Hemophilia. [cited 2017 Jan 4]; 2012. Available from: http://www1.wf.org/publication/fles/pdf-1471.pdf
Goldman RD, Blanchette V, Koren G. Hemophilia during pregnancy. Can Fam Physician. 2003;49:1601–3.
Mauser Bunchoten Evelin. Symptomatic Carriers of Hemophilia. Montreal: World Federation of Hemophilia. [cited 2017 Jan 4]; 2008;(46). Available from: http://www1.wf.org/publication/fles/pdf-1190.pdf.
Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AHJT, Amstel HKP van, Bom JG van der, Diemen-Homan JEM van, et al. Bleeding in carriers of hemophilia. Blood. 2006;108(1):52–6.
Paroskie A, Oso O, Almassi B, DeBaun MR, Sidonio RF. Both hemophilia health care providers and hemophilia a carriers report that carriers have excessive bleeding. J Pediatr Hematol Oncol. 2014;36(4):e224–230.
Paroskie A, Gailani D, DeBaun MR, Sidonio RF. A cross-sectional study of bleeding phenotype in haemophilia A carriers. Br J Haematol. 2015;170(2):223–8.
Peyvandi F, Garagiola I, Mortarino M. Prenatal diagnosis and preimplantation genetic diagnosis: novel technologies and state of the art of PGD in different regions of the world. Haemophilia. 2011;17 Suppl 1:14–7.
Evans MI, Andriole S. Chorionic villus sampling and amniocentesis in 2008. Curr Opin Obstet Gynecol. 2008;20(2):164–8.
Jauniaux E, Pahal GS, Rodeck CH. What invasive procedure to use in early pregnancy? Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14(4):651–62.
Tabor A, Alfrevic Z. Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ter. 2010;27(1):1–7.
Wapner RJ. Invasive prenatal diagnostic techniques. Semin Perinatol. 2005;29(6):401–4.
Olney R, Moore C, Khourty M, Ericson J, Edmonds L, Botto L. Chorionic Villus Sampling and Amniocentesis: Recommendations for Prenatal Counseling. CDC, MMWR, Recommendations and Reports. 1995 [cited 2017 May 14]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/00038393.htm.
Tul Mandič N, Slavec Jere K. Invazivni intrauterini posegi v nosečnsti. In: Tul Mandič N, editor. Ultrazvočne preiskave v ginekologiji in perinatologiji. Ljubljana: Združenje za perinatalno medicino; 2017;p. 183–8.
Mortarino M, Garagiola I, Lotta LA, Siboni SM, Semprini AE, Peyvandi F. Non-invasive tool for foetal sex determination in early gestational age. Haemophilia. 2011;17(6):952–6.
Rijnders RJP, Van Der Luijt RB, Peters EDJ, Goeree JK, Van Der Schoot CE, Ploos Van Amstel JK, et al. Earliest gestational age for fetal sexing in cell-free maternal plasma. Prenat Diagn. 2003;23(13):1042–4.
Chi C, Hyett JA, Finning KM, Lee CA, Kadir RA. Non-invasive frst trimester determination of fetal gender: a new approach for prenatal diagnosis of haemophilia. BJOG Int J Obstet Gynaecol. 2006;113(2):239–42.
Kletzel M, Miller CH, Becton DL, Chadduck WM, Elser JM. Postdelivery head bleeding in hemophilic neonates. Causes and management. Am J Dis Child 1960. 1989;143(9):1107–10.
Chi C, Lee CA, Shiltagh N, Khan A, Pollard D, Kadir RA. Pregnancy in carriers of haemophilia. Haemophilia. 2008;14(1):56–64.
Huq FY, Kadir RA. Management of pregnancy, labour and delivery in women with inherited bleeding disorders. Haemophilia. 2011;17 Suppl 1:20–30.
Economou M, Banov L, Ljung R. Perinatal aspects of haemophilia. Eur J Haematol Suppl. 2014;76:21–5.
Nichols WL, Hultin MB, James AH, MancoJohnson MJ, Montgomery RR, Ortel TL, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171–232.
Kulkarni R, Soucie JM, Lusher J, Presley R, Shapiro A, Gill J, et al. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention’s (CDC) Universal Data Collection (UDC) project. Haemophilia. 2009;15(6):1281–90.
Chalmers E, Williams M, Brennand J, Liesner R, Collins P, Richards M, et al. Guideline on the management of haemophilia in the fetus and neonate. Br J Haematol. 2011;154(2):208–15.
Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol. 1990;12(1):95–104.
Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Tromb Haemost. 2006;95(2):362–72.
Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the full-term infant. Blood. 1987;70(1):165–72.
Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the healthy premature infant. Blood. 1988;72(5):1651–7.
Cornelissen M, Kries R von, Loughnan P, Schubiger G. Prevention of vitamin K deficiency bleeding: efficacy of different multiple oral dose schedules of vitamin K. Eur J Pediatr. 1997;156(2):126–30.
Hansen KN, Minousis M, Ebbesen F. Weekly oral vitamin K prophylaxis in Denmark. Acta Paediatr. 2003;92(7):802–5.
Price VE, Hawes SA, Chan AK. A practical approach to hemophilia care in children. Paediatr Child Health. 2007;12(5):381–3.
Richards M, Lavigne Lissalde G, Combescure C, Batorova A, Dolan G, Fischer K, et al. Neonatal bleeding in haemophilia: a European cohort study. Br J Haematol. 2012;156(3):374–82.
Kulkarni R, Lusher JM, Henry RC, Kallen DJ. Current practices regarding newborn intracranial haemorrhage and obstetrical care and mode of delivery of pregnant haemophilia carriers: a survey of obstetricians, neonatologists and haematologists in the United States, on behalf of the National Hemophilia Foundation’s Medical and Scientifc Advisory Council. Haemophilia. 1999;5(6):410–5.
Bidlingmaier C, Bergmann F, Kurnik K. Haemophilia A in two premature infants. Eur J Pediatr. 2005;164(2):70–2.
Poon M-C, Lillicrap D, Hensman C, Card R, Scully M-F. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Tromb Haemost. 2002;87(3):431–5.
Guilcher GMT, Scully M-F, Harvey M, Hand JP. Treatment of intracranial and extracranial haemorrhages in a neonate with severe haemophilia B with recombinant factor IX infusion. Haemophilia. 2005;11(4):411–4.
Carpenter SL, Soucie JM, Presley RJ, Ragni MV, Wicklund BM, Silvey M, et al. Hepatitis B vaccination is effective by subcutaneous route in children with bleeding disorders: a universal data collection database analysis. Haemophilia. 2015;21(1):e39–43.
Kulkarni R, Lusher J. Perinatal management of newborns with haemophilia. Br J Haematol. 2001;112(2):264–74.
Evans DI, Shaw A. Safety of intramuscular injection of hepatitis B vaccine in haemophiliacs. BMJ. 1990;300(6741):1694–5.
Philipp C. Te aging patient with hemophilia: complications, comorbidities, and management issues. Hematology Am Soc Hematol Educ Program. 2010;2010:191–6.
Angelini D, Sood SL. Managing older patients with hemophilia. Hematology Am Soc Hematol Educ Program. 2015;2015:41–7.
Mauser-Bunschoten EP, Fransen Van De Putte DE, Schutgens REG. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia. 2009;15(4):853–63.
Angelini D, Konkle BA, Sood SL. Aging among persons with hemophilia: contemporary concerns. Semin Hematol. 2016;53(1):35–9.
Zimmermann R, Staritz P, Huth-Kühne A. Challenges in treating elderly patients with haemophilia: a focus on cardiology. Tromb Res. 2014;134 Suppl 1:S48–52.
Staritz P, Moerloose P de, Schutgens R, Dolan G, ADVANCE Working Group. Applicability of the European Society of Cardiology guidelines on management of acute coronary syndromes to people with haemophilia–an assessment by the ADVANCE Working Group. Haemophilia. 2013;19(6):833–40.
Dolan G. The challenge of an ageing haemophilic population. Haemophilia. 2010;16 Suppl 5:11–6.
Schutgens REG, Tuinenburg A, Fischer K, Mauser-Bunschoten EP. Anticoagulation therapy in haemophilia. Managing the unknown. Hamostaseologie. 2013;33(4):299–304.
Schutgens REG, Klamroth R, Pabinger I, Dolan G, ADVANCE working group. Management of atrial fibrillation in people with haemophilia—a consensus view by the ADVANCE Working Group. Haemophilia. 2014;20(6):e417–420.
Buzzard BM. Physiotherapy for prevention and treatment of chronic hemophilic synovitis. Clin Orthop. 1997;(343):42–6.
Elander J, Robinson G, Mitchell K, Morris J. An assessment of the relative influence of pain coping, negative thoughts about pain, and pain acceptance on health-related quality of life among people with hemophilia. Pain. 2009;145(1–2):169–75.
Genderen FR van, Fischer K, Heijnen L, Kleijn P de, Berg HM van den, Helders PJM, et al. Pain and functional limitations in patients with severe haemophilia. Haemophilia. 2006;12(2):147–53.
Wallny T, Hess L, Seuser A, Zander D, Brackmann HH, Kraf CN. Pain status of patients with severe haemophilic arthropathy. Haemophilia. 2001;7(5):453–8.
Riley RR, Witkop M, Hellman E, Akins S. Assessment and management of pain in haemophilia patients. Haemophilia. 2011;17(6):839–45.
Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol. 1993;30(3 Suppl 2):3–6.
Feldman BM, Funk S, Lundin B, Doria AS, Ljung R, Blanchette V. Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG). Haemophilia. 2008;14:162–9.
Feldman BM, Funk SM, Bergstrom B-M, Zourikian N, Hilliard P, Net J van der, et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res. 2011;63(2):223–30.
Copyright (c) 2017 Slovenian Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
